GUEST COLUMNISTS

• Can Your Team Coordinate The CRO Model You've Chosen?

  Choosing the right CRO model matters less than a sponsor’s ability to coordinate it. Here’s how to match outsourcing strategy to internal capacity.

• To Pick The Right Medical LLM, First Assess Your Readiness

  Learn how to evaluate medical LLMs for clinical trials by weighing readiness, risk, validation, integration, hidden costs, and supplier controls.

• Your Company Needs Compliance Expertise — But When And From Whom?

  When should a biotech formalize compliance? Learn how risk, funding, clinical activity, and commercialization shape the right expertise and structure.

• 5 Sponsor Contracting Issues That Delay Clinical Trials — And How To Avoid Them

  CTA negotiations don’t have to stall study start-up. Learn five sponsor-side contracting issues that cause delays and practical ways to prevent them.

• Participant Payment — Make It Make Cents

  Participant payment practices and expectations vary wildly. With advocate T.J. Sharpe, explore why sponsors need to rethink how they appreciate participants' time, effort, and burden.

• What Ecological Momentary Assessment Taught Us About Real-World Hearing Outcomes

  Ecological momentary assessment (EMA) reveals how people experience hearing challenges beyond the clinic. Here, researchers highlight its relevance in designing real-world hearing studies.

• Calidi's Study Aims To Have An Oncolytic Virus Outsmart The Immune System

  Calidi’s Eric Poma, Ph.D., explains how CLD-401 could evade immune clearance — and how the biotech is designing Phase 1 to prove safety and efficacy fast.

• New Imaging Approach Could Improve IPF Trial Design

  AI-powered quantitative CT could help sponsors detect treatment effects earlier, strengthen IPF trial endpoints, and make better go/no-go decisions.